1146957-64-3

Upstream product

• 53449-14-2 7-chloro-6-nitro-4(3H)-quinazolinone 
• 89-77-0 2-Amino-4-chlorobenzoic acid 
• 55496-69-0 4-chloro-7-methoxy-6-nitroquinazoline 
• 1012057-47-4 7-methoxy-6-nitroquinazolin-4(3H)-one 
• 1012057-48-5 N-(3-chloro-4-fluorophenyl)-7-methoxy-6-nitroquinazolin-4-amine hydrochloride 
• 31374-18-2 7-chloro-3,4-dihydroquinazolin-4-one 
• 179552-75-1 N⁴-(3-chloro-4-fluorophenyl)-7-methoxyquinazoline-4,6-diamine 
• 1501-26-4 methyl 4-(chlorocarbonyl)butyrate 
• 179552-74-0 N-(3-chloro-4-fluorophenyl)-7-methoxy-6-nitroquinazolin- 4-amine 

Downstream Products

• 1012054-73-7 N₁-(4-(3-chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl)-N₅-hydroxyglutaramide 

Relevant academic research and scientific papers

TARTRATE SALTS OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY

The present invention relates to tartrate salts of quinazoline containing zinc-binding moiety based derivatives that are inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The tartrate salts may further act as HDAC inhibitors.

FORMULATION OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY

The present invention relates to a composition comprising an inclusion complex of a cyclodextrin and quinazoline containing zinc-binding moiety based derivatives. The cyclodextrin is preferable a β-cyclodextrin or a derivative thereof. The quinazolines have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.